EADC: European Aortic Data Collection Project

Sponsor
Cook Research Incorporated (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05896397
Collaborator
(none)
600
2
90.1
300
3.3

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the safety and performance of Cook's various Custom-Made Stent-graft Devices (CMD) used for endovascular treatment of the aorta and related diseases by collecting information on the real-world use of the devices.

The study results will be used to support the continuation of the CMDs on the market. In addition, the study will support the manufacturers obligation for post market product surveillance as well as Cook's technology development.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Endovascular Aortic Treatments

Study Design

Study Type:
Observational
Anticipated Enrollment :
600 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
European Aortic Data Collection Project
Actual Study Start Date :
May 31, 2023
Anticipated Primary Completion Date :
Dec 1, 2026
Anticipated Study Completion Date :
Dec 1, 2030

Outcome Measures

Primary Outcome Measures

  1. Rate of treatment success [12 months]

    Procedural treatment success is defined as successful access to the arterial system using remote arterial exposure, percutaneous technique or open surgical conduits. Success is also defined as successful delivery and deployment of the aortic graft and all stent components, side branch catheterization and placement of bridging stents and patency of all aortic modular stent graft components and intended side branch components.

  2. Rate of safety outcomes [30 days]

    Safety outcomes is defined as freedom from major adverse events (all-cause mortality, myocardial infarction, disabling stroke, renal failure requiring new-onset dialysis, respiratory failure requiring prolonged (>24hrs) mechanical ventilation or reintubation, paraplegia, bowel ischemia requiring surgical resection or not resolving with medical therapy)

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Patients who will be treated with a Cook CMD
Exclusion Criteria:
  1. Patients who declare they are unable to complete clinical follow-up visit at the time of enrollment, or

  2. Patients or his/her legally authorized representative objects to extraction of patient's data from the medical record, or unwilling to sign the Informed Consent.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hopital Marie Lannelongue Le Plessis-Robinson France 92350
2 CHU de Lille Lille France 59037

Sponsors and Collaborators

  • Cook Research Incorporated

Investigators

  • Principal Investigator: Stephan Haulon, MD,PhD, Hopital Marie Lannelongue

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Cook Research Incorporated
ClinicalTrials.gov Identifier:
NCT05896397
Other Study ID Numbers:
  • MDR-2091
First Posted:
Jun 9, 2023
Last Update Posted:
Jun 15, 2023
Last Verified:
Jun 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Cook Research Incorporated
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 15, 2023